This clinical trial is focused on studying a type of cancer called Splenic Marginal Zone Lymphoma (SMZL), which affects a part of the immune system known as the spleen. The study is investigating the effectiveness of a treatment that combines two medications: Rituximab and Zanubrutinib. Rituximab is a medication that is given through an infusion into a vein, while Zanubrutinib, also known by its code name BGB-3111, is taken orally in capsule form. The purpose of the study is to see if adding Zanubrutinib to Rituximab is more effective than using Rituximab alone in treating patients who have not received any previous treatment for their SMZL.

Participants in the study will be randomly assigned to receive either the combination of Rituximab and Zanubrutinib or Rituximab alone. The study will last for up to 24 months, during which time the participants will receive their assigned treatment. The researchers will monitor the participants’ health and the progression of their lymphoma throughout the study period. The main goal is to determine how long the participants can live without their disease getting worse, which is known as progression-free survival.

By comparing the two treatment approaches, the study aims to provide valuable information on whether the addition of Zanubrutinib can improve outcomes for patients with SMZL. The results could potentially lead to better treatment options for individuals diagnosed with this type of lymphoma. Participants will be closely monitored for any side effects or adverse reactions to the medications, ensuring their safety throughout the trial.